|
|
|
|
|
|
by assadk
2347 days ago
|
|
|
> The company is focused on a class of molecule known cyclodextrins, and have candidates capable of efficiently binding and sequestering 7-ketocholesterol. This form of oxidized cholesterol is of great importance to the progression of atherosclerosis, and possibly other age-related conditions as well. The thing is cyclodextrins have been linked to causing deafness, in as little as a week. As per
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5676048/ and https://www.wsj.com/amp/articles/deaf-or-death-in-drug-trial... Heart disease or hearing – tough trade-offs. Here’s to hoping that they’ve engineered a novel compound without any of the downsides. |
|
|